铂耐药卵巢癌的免疫治疗.pdfVIP

铂铂耐耐药药卵卵巢巢癌癌的的免免疫疫治治疗疗 暨2017卵巢癌临床重要进展 概概 述述 卵卵巢巢癌癌是是常常见见的的恶恶性性肿肿瘤瘤，，估估计年全全美美初初诊诊患患者者达达2222228800人人，， 亡亡1144224400人人，，位位列列女女性性肿肿瘤瘤相相关关 因因的的第第五五。年全全球球初初诊诊卵卵巢巢癌癌 发发病病人人数数估估计计高高达达223399000000人人。。由由于于卵卵巢巢癌癌起起病病隐隐匿匿，，早早期期无无明明显显症症状状，， 诊诊断断时时多多为为晚晚期期。。虽虽然然手手术术、、化化疗疗对对卵卵巢巢癌癌有有效效，，但但超超过过7700%%患患者者缓缓解解 后后将将要要复复发发，，因因此此，，卵卵巢巢癌癌患患者者很很少少能能活活过过五五年年。。 Comparedwith other cancers, ovarian cancer isrelatively uncommon,with an estimated 22,280 new diagnoses in theUnited States in 2016.Worldwide, 239,000women were diagnosedwith ovarian cancer in 2012.Nonetheless, ovarian cancer is the fifth most common cause of cancer-related death among USwomen, causing an estimated 14,240 deaths in 2016.Because of the lack of specific symptoms, ovarian cancer has often reached an advanced stageby the time of diagnosis.Despite surgery and chemotherapy,more than 70% of women with ovarian cancer that goes into remission eventually experience a relapse.Fewer than half of such women live 5 yearsafter diagnosis. RReeccuurrrreenntt OOvvaarriiaann CCaanncceerr 根根据据对对铂铂化化疗疗的的敏敏感感性性将将复复发发性性卵卵巢巢癌癌分分为为 个个类类型型 RReeccuurrrreenntt OOvvaarriiaann CCaanncceerr WWhhaatt iiss tthhee PPFFII ((PPllaattiinnuumm--FFrreeee IInntteerrvvaall ))?? ((IInntteerrvvaall ffrroomm llaasstt ddaattee ooff ppllaattiinnuumm ddoossee uunnttiillpprrooggrreessssiioonn)) PPllaattiinnuumm--FFrreeee IInntteerrvvaall aanndd SSuurrvviivvaall PPFFII可可能能是是影影响响再再次次化化疗疗疗疗效效的的重重要要独独立立因因素素 因因此此有有学学者者提提出出通通过过非非铂铂 药药物物治治疗疗使使无无铂铂治治疗疗间间期期延延长长 （（PPFFII））改改善善复复发发性性卵卵巢巢癌癌再再次次用用铂铂化化疗疗的的敏敏感感性性。。 PPFFII 66--1122个个月月 有有效效率率 2222%% 大大于于1122--2244个个月月 3311%% 大大于于2244个个月月 5599%%